Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 307Breast 196Sarcoma 112Other hematologic neoplasm 101Gynecologic 43CNS 38Genitourinary 37Gastrointestinal 34Plasma cell 26Thoracic 13Other solid neoplasm 13Endocrine 10Head & Neck 8Tumor-Agnostic 7Dermatologic 5Myeloid 4Classical hematology 3NET 2Other 1

Conditions

Neuroendocrine Tumors 2Neoplasms 2Neoplasm Metastasis 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Doxorubicin × NET × Clear all
NCT01678664 2024-09-25

EVACEL

Federation Francophone de Cancerologie Digestive

Phase 2 Completed
74 enrolled 10 charts
EndocrineNET

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

PharmaMar

Phase 1 Completed
122 enrolled 19 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡